Psychemedics Corp Stock Price, News & Analysis

Psychemedics Corporation (NASDAQ:PMD) reported Q1 2021 revenue of $5.7 million, down 24% from $7.5 million in Q1 2020. However, net income improved to $0.1 million ($0.01 per share) compared to a net loss of $0.2 million (-$0.03 per share) last year, driven by a $0.8 million Employee Retention Credit. Domestic revenues fell 15% year-over-year, while international volumes remained significantly low. The company, holding $2.2 million in cash, expressed confidence in returning to profitable growth as the economy recovers, though it suspended dividends during the pandemic.

Psychemedics Corporation (NASDAQ:PMD) reported a significant decline in financial performance for the year ending December 31, 2020. Revenue decreased by 43% to $21.4 million, with a net loss of $3.9 million, or $0.70 per diluted share, compared to a net income of $1.5 million in 2019. The fourth quarter also saw a 39% drop in revenue to $5.3 million. Despite challenges from the COVID-19 pandemic, the company is optimistic about recovery, citing improved testing volumes and a strong balance sheet with $2.8 million in cash. The company aims for profitable growth while evaluating dividend resumption.

Psychemedics Corporation (NASDAQ: PMD) has appointed Robyn C. Davis to its Board of Directors, following the passing of Clint Allen. Ms. Davis brings extensive experience in life sciences and strategy, having served on the boards of prominent companies like Brooks Automation and Akston Bioscience. She is a Managing Director at Angel Healthcare Investors and has advised various organizations on growth strategies. The company is a leader in drug testing, utilizing its patented hair testing method preferred by many Fortune 500 companies.

Psychemedics Corporation (NASDAQ: PMD) has appointed Andrew Limbek as Vice President, Controller. Andrew brings over 12 years of experience in financial activities, including external reporting and internal analysis. He has worked with prominent accounting advisory firms and held operational roles, including Controller at Racepoint Global, Inc. His educational background includes a Bachelor of Science in Accounting from the University of New Hampshire. CEO Raymond C. Kubacki emphasizes Andrew's technical expertise and financial analysis skills as pivotal for the company’s growth strategy.

Psychemedics Corporation (NASDAQ: PMD) announces the reappointment of Sarah Ashby as Vice President, General Counsel. She will oversee all legal activities and report to the CEO. Sarah's prior experience includes roles at Decibel Therapeutics and Takeda Pharmaceutical, focusing on R&D, toxicology studies, and clinical trials. CEO Raymond C. Kubacki emphasized the strategic importance of her role in supporting clients with legal challenges. Psychemedics is the largest provider of hair testing for drug abuse detection, serving numerous clients, including Fortune 500 companies.

Psychemedics Corporation (NASDAQ:PMD) announced a 47% revenue decline to $5.2 million for Q3 2020, with a net loss of $1.1 million compared to a profit of $0.7 million in Q3 2019. Year-to-date revenues fell 45% to $16.0 million, with a net loss of $3.3 million. Despite ongoing challenges from COVID-19, the company reported a 56% revenue increase from Q2 2020. Domestic sales decreased by 30% year-over-year but improved by 56% from Q2 2020. The company noted a significant drop in international revenues (93%) due to closures in Brazil. It has plans for cost-cutting measures and a focus on recovery.

Psychemedics Corporation (NASDAQ:PMD) reported a sharp decline in second quarter revenue, earning $3.3 million compared to $9.3 million a year prior, marking a 64% decrease. The net loss was $2.1 million, translating to ($0.37) per diluted share, contrasting with a net income of $0.8 million or $0.14 per share in 2019. The COVID-19 pandemic affected domestic revenue significantly, which fell by 54%. Despite challenges, the company received a $2.2 million PPP loan, anticipating $1.7 million forgiveness. The company has suspended its dividend after 94 consecutive payments.

Psychemedics Corporation (NASDAQ:PMD) reported a 23% revenue decline in Q1 2020, totaling $7.5 million compared to $9.8 million in Q1 2019. A net loss of $0.2 million or ($0.03) per diluted share was recorded, contrasting with a net income of $0.6 million or $0.11 per diluted share last year. The 34% drop in sales volume, influenced by COVID-19, was partially offset by an 11% revenue per sample increase. The company secured a $2.2 million loan from the Paycheck Protection Program to maintain operations. Despite challenges, they introduced an FDA-cleared nicotine test in April.